Bortezomib-induced Posterior Reversible Encephalopathy Syndrome in a Patient with Newly Diagnosed Multiple Myeloma

Gaku Oshikawa; Akira Kojima; Noriko Doki; Takeshi Kobayashi; Kazuhiko Kakihana; Hiromasa Tsuda; Ikuyo Endo; Noriko Kamata; Kazuteru Ohashi; Hisashi Sakamaki

doi:10.2169/internalmedicine.52.8799

CASE REPORTS

Bortezomib-induced Posterior Reversible Encephalopathy Syndrome in a Patient with Newly Diagnosed Multiple Myeloma

Gaku Oshikawa, Akira Kojima, Noriko Doki, Takeshi Kobayashi, Kazuhiko Kakihana, Hiromasa Tsuda, Ikuyo Endo, Noriko Kamata, Kazuteru Ohashi, Hisashi Sakamaki

Author information

Gaku Oshikawa
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
Akira Kojima
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
Noriko Doki
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
Takeshi Kobayashi
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
Kazuhiko Kakihana
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
Hiromasa Tsuda
Neurology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
Ikuyo Endo
Radiology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
Noriko Kamata
Radiology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
Kazuteru Ohashi
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
Hisashi Sakamaki
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan

Keywords: PRES, bortezomib, multiple myeloma

JOURNAL OPEN ACCESS

2013 Volume 52 Issue 1 Pages 111-114

DOI https://doi.org/10.2169/internalmedicine.52.8799

Details

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a known but extremely rare side effect of bortezomib therapy. An unusual case of PRES possibly caused by bortezomib during induction treatment in a patient with multiple myeloma is reported. The patient experienced neither hypertensive crisis nor uremic encephalopathy at the onset of PRES, which are both well-known etiologies of PRES. The patient's PRES-related symptoms resolved completely after discontinuation of bortezomib and administration of a bulk dose of corticosteroids. The importance of early recognition of this potential neurological complication must be emphasized because this new drug is being increasingly prescribed.

Corresponding author

Register with J-STAGE for free!